The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
How basal are triple‐negative breast cancers?
Open accessAbstract
The basal molecular subtype of breast cancer (BC) is defined by the mRNA expression pattern of an intrinsic ∼500‐gene set. It is the most homogeneous subtype in transcriptional terms, and one of the most aggressive in prognostic terms. Clinical trials testing new systemic therapeutic strategies have been launched in basal BCs. Although no proof of evidence has yet been reported, basal tumors are currently assimilated to and selected as triple‐negative (TN) BCs in these trials because of their frequent immunohistochemical (IHC) negativity for hormone and ERBB2 receptors. Here, we have assessed the degrees of correlation and of homogeneity of the TN phenotype (IHC‐based definition) and the basal subtype (gene expression‐based definition). We analyzed 172 TN BCs defined by gene expression profile as basal (123 cases) and nonbasal (49 cases). Conversely, 160 tumors were defined as basal by their gene expression profile and included 123 TN and 37 non‐TN samples. Uni‐ and multivariate analyses revealed that TN BCs represent a more heterogeneous group than basal BCs, including basal and nonbasal tumors very different both at the histoclinical and molecular level, notably for mRNA expression of molecules targeted by specific therapies under evaluation in clinical trials. These results call for caution in the interpretation of ongoing trials and selection of patients in future trials. They also warrant the identification of molecular markers for basal BCs more clinically applicable than gene expression profiles. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
The molecular portraits of breast tumors are conserved across microarray platforms
Hu, Z., Fan, C., Oh, D. S., Marron, J., He, X., Qaqish, B. F., Livasy, C., Carey, L. A., Reynolds, E., Dressler, L., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-96 · Cited by 1,491
Prognostic markers in triple‐negative breast cancer
Rakha, E. A., El‐Sayed, M. E., Green, A. R., Lee, A. H. S., Robertson, J. F., & Ellis, I. O. (2007) · Cancer · doi:10.1002/cncr.22381 · Cited by 1,283
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063
Triple-negative breast cancer: therapeutic options
Cleator, S., Heller, W., & Coombes, R. C. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70074-8 · Cited by 882
Hess, K. R., Anderson, K., Symmans, W. F., Valero, V., Ibrahim, N., Mejia, J. A., Booser, D., Theriault, R. L., Buzdar, A. U., Dempsey, P. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6861 · Cited by 721
Kreike, B., van Kouwenhove, M., Horlings, H., Weigelt, B., Peterse, H., Bartelink, H., & van de Vijver, M. J. (2007) · Breast Cancer Research · doi:10.1186/bcr1771 · Cited by 613
Sørlie, T., Wang, Y., Xiao, C., Johnsen, H., Naume, B., Samaha, R. R., & Børresen-Dale, A.-L. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-127 · Cited by 387
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
Tischkowitz, M., Brunet, J.-S., Bégin, L. R., Huntsman, D. G., Cheang, M. C., Akslen, L. A., Nielsen, T. O., & Foulkes, W. D. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-134 · Cited by 365
Tan, D. S. P., Marchió, C., Jones, R. L., Savage, K., Smith, I. E., Dowsett, M., & Reis-Filho, J. S. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9756-8 · Cited by 318
Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers
Bertucci, F., Finetti, P., Cervera, N., Charafe-Jauffret, E., Mamessier, E., Adélaïde, J., Debono, S., Houvenaeghel, G., Maraninchi, D., Viens, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0031 · Cited by 310
Self-citationIntegrated Profiling of Basal and Luminal Breast Cancers
Adélaïde, J., Finetti, P., Bekhouche, I., Repellini, L., Geneix, J., Sircoulomb, F., Charafe-Jauffret, E., Cervera, N., Desplans, J., Parzy, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2536 · Cited by 297
Self-citationB-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer
Moyano, J. V. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25888 · Cited by 272
Gene Expression Profiling Identifies Molecular Subtypes of Inflammatory Breast Cancer
Bertucci, F., Finetti, P., Rougemont, J., Charafe-Jauffret, E., Cervera, N., Tarpin, C., Nguyen, C., Xerri, L., Houlgatte, R., Jacquemier, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4115 · Cited by 237
Self-citationDeconstructing the molecular portrait of basal-like breast cancer
Yehiely, F., Moyano, J. V., Evans, J. R., Nielsen, T. O., & Cryns, V. L. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.09.004 · Cited by 144
Discovery and validation of breast cancer subtypes
Kapp, A. V., Jeffrey, S. S., Langerød, A., Børresen‐Dale, A., Han, W., Noh, D., Bukholm, I. R., Nicolau, M. M., Brown, P. O., & Tibshirani, R. J. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-231 · Cited by 129
Are triple-negative tumours and basal-like breast cancer synonymous?
Rakha, E. A., Tan, D. S. P., Foulkes, W. D., Ellis, I. O., Tutt, A. N. J., Nielsen, T. O., & Reis-Filho, J. S. (2007) · Breast Cancer Research · doi:10.1186/bcr1827 · Cited by 126
Yu, K., Lee, C. H., Tan, P. H., & Tan, P. B. O. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0085 · Cited by 124
Bidard, F., Conforti, R., Boulet, T., Michiels, S., Delaloge, S., & André, F. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm360 · Cited by 87
Reyal, F., Stransky, N., Bernard‐Pierrot, I., Vincent‐Salomon, A., Rycke, Y. D., Elvin, P., Cassidy, A., Graham, A., Spraggon, C., Désille, Y., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2706 · Cited by 83
Sasa, M., Bando, Y., Takahashi, M., Hirose, T., & Nagao, T. (2007) · Journal of Surgical Oncology · doi:10.1002/jso.20906 · Cited by 44
Cited by
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,742
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
Role of epidermal growth factor receptor in breast cancer
Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2289-9 · Cited by 806
Metadata
- Authors
- Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., & Birnbaum, D.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2008-04-24
- Volume
- 123
- Issue
- 1
- Pages
- 236-240
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2035077913
- Cited by
- 443
- References
- 29
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.